Radix Angelicae Sinensis and Radix Hedysari Enhance Radiosensitivity of Human Liver Cancer Cells to 12C6+ Radiation

DOU Chun-jiang, KOU Wei, LI Ying-dong. et al

Abstract

To determine the effect of Radix Angelicae Sinensis and Radix Hedysari （RAS-RH） on radiosensitivity of human liver cancer H22 cells to heavy ion 12C6+ and its possible mechanism. MethodsThe experiment involved a comparison of proliferation of H22 cells (detected by CCK-8 assay) between four groups: control, drug (RAS-RH), radiation, and combination (RAS-RH+radiation). H22 cells were treated with different doses of radiation alone or radiation followed by RAS-RH. The radiation enhancement effect of RAS-RH on H22 was detected by Colony forming assay. The effect of RAS-RH on the apoptosis of H22 cells was detected by flow cytometry. The influence of RAS-RH on the expression levels of related protein Survivin and Caspase-9 was investigated by Western blot. ResultsRAS-RH inhibited the proliferation of H22 cells, with a time and dose dependency 〔inhibitory concentration 20% (IC20)=(117.60±2.15) mg/L〕. The survival rate of H22 cells decreased significantly with the increase of heavy ion 12C6+. The two survival curves produced by the Graph Pad Prism 5.0 software were clearly separated. The combination group demonstrated smaller shoulder area at low dosage and lower survival rate of cells compared with radiation group, with a sensitization enhancement ratio (SER) of 1.39±0.07. The combination group (100 mg/L RAS-RH+2 Gy) had higher apoptosis rate and Caspase-9 protein expression level, and lower Survivin protein expression level, compared with other 3 groups ( P<0.01). ConclusionRAS-RH has radiation sensitization effect on human hepatocellular carcinoma H22 cells. The mechanism may be related to down-regulation of Survivin protein expression and up regulation of Caspase-9 protein expression.

 

Keywords:  Radix Angelicae, Sinensis and Radix Hedysari, Human hepatocellular carcinoma H22 cells Heavy ion 12C6+Apoptosis, Radiosensitivity 

 

 

Full Text:

PDF


References


BINDER D. TEMMESFELD-WOLLBRUCK B. WURM R, et al. Brain metastases of lung cancer. Dtsch Med Wochenschr,2006,131(4): 165-171.

ZIMMERMANN S, DZIADZIUSZKO R, PETERS S. Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases. Cancer Treat Rev, 2014,40(6); 716-722.

LEE HW, LEE JI, LEE SJ, et al. Patient-derived xenografts from non-small cell lung cancer brain metastases are valuable translational platforms for the development of personalized targeted therapy. Clin Cancer Res,2015 ,21 (5): 1172-1182.

JONSSON F, YIN L, LUNDHOLM C, et al. Low-dose aspirin use and cancer characteristics: a population-based cohort study. Br J Cancer,2013,109(7); 1921-1925.

ZHONG X, FAN Y, RITZENTHALER JD, et al. Novel link between prostaglandin E2 ( PGE2 ) and cholinergic signaling in lung cancer: the role of c-Jun in PGE2-induced al nicotinic acetylcholine receptor expression and tumor cell proliferation. Thorac Cancer,2015,6(4);488-500.

HARFORD-WRIGHT E, LEWIS KM, VINK R. Towards drug discovery for brain tumours: interaction of kinins and tumours at the blood brain barrier interface. Recent Pat CNS Drug Discov,2011,6( 1);31-40.

THOMPSON EM. FRENKEL EP, NEUWELT EA. The paradoxical effect of bevacizumab in the therapy of malignant gliomas. Neurology,2011,76(1):87-93.

LEMASSON B, SERDUC R, MAISIN C, et al. Monitoring blood-brain barrier status in a rat model of glioma receiving therapy, dual injection of low-molecular-weight and macromolecular MR contrast media. Radiology, 2010, 257 (2):342-352.

PANG Z. FENG L« HUA R, et al. Lactoferrin-conjugated biodegradable polymersome holding doxorubicin and tetrandrine for chemotherapy of glioma rats. Mol Pharm, 2010,7(6):1995-2005.

BLACK KL, YIN D. ONG JM. et al. PDE5 inhibitors enhance tumor permeability and efficacy of chemotherapy in a rat brain tumor model. Brain Res,2008,1230;290-302[2016- 10-10]. http://www. sciencedirect. com/science/article/pii/ S0006899308016028. doi: 10. 1016/j. brainres. 2008. 06. 122.

CHO MS, VASQUEZ HG, RUPAIMOOLE R, et al. Autocrine effects of tumor-derived complement. Cell Rep, 2014,6(6):1085-1095.

ZIMMERMANN S, DZIADZIUSZKO R. PETERS S.

Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases. Cancer Treat Rev,2014,40(6):716-722.

BA ENA CP. D’ AM ICO RC, SLONGO H. et al. The effectiveness of aspirin for migraine prophylaxis; a systematic review. Sao Paulo Med J.2017,135(1) ;42-49.

ZHU HM, WU T, CUI L. Study of aspirin on proliferation and apoptosis of human lung Adenocarcinoma cell lines SPCA-1 in vivo. Chinese Pharmacological Bulletin. 2004 , 20 (6):640-643.

FUKUMOTO K. TAKAGI N, YAMAMOTO R. et al. Prostanoid EP1 receptor antagonist reduces blood-brain barrier leakage after cerebral ischemia. Eur J Pharmacol, 2010,640(1/2/3) ;82-86.

KOU W. LI YD. LIU K. et al. Radix Angelicae Sinensis and Radix Hedysari enhance radiosensitivity of 12CG" radiation in human liver cancer cells by modulating apoptosis protein. Saudi Med J ,2014,35(9):945-952.

HARTLERODE AJ, MORGAN MJ, WU Y, et al. Recruitment and activation of the ATM kinase in the absence of DNA damage sensors. Nat Struct Mol Biol, 2015,22(9): 736-743.

FU T, WANG L, JIN X, et al. Hyperoside induces both autophagy and apoptosis in non-small cell lung cancer cells in vitro. Acta Pharm Sin.2016,37(4):505-518.

BOMMER UA, IADEVAIA V, CHEN J, et al. Growth- factor dependent expression of the translationally controlled tumour protein TCTP is regulated through the Pl3-K/Akt/ mTORCl signalling pathway. Cell Signal,2015,27(8): 1557- 1563.

CHUX, CHEN L, WANG J, et at. SiRNA-mediated surviving inhibition enhances chemo-or radiosensivity of colorectal cancer cells in tumor-bearing nude mice. Hepatogastroenterology,2012, 57(104 ); 1445-1452.


Refbacks

  • There are currently no refbacks.